The Journal of Urology
Volume 177, Issue 6 , Pages 2146-2150 , June 2007

Phase II Study of Low Dose and High Dose Conjugated Estrogen for Androgen Independent Prostate Cancer

Received 4 October 2006

References 

  1. Jemal A, Siegel R, Ward E, Murray T, Xu J, Smigal C, et al. Cancer statistics, 2006. CA Cancer J Clin. 2006;56:106
  2. Smaletz O, Scher HI, Small EJ, Verbel DA, McMillan A, Regan K, et al. Nomogram for overall survival of patients with progressive metastatic prostate cancer after castration. J Clin Oncol. 2002;20:3972
  3. Huggins C, Hodges C. Studies on prostate cancer I (The effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate). Cancer Res. 1941;1:293
  4. Nesbit R, Baum W. Endocrine control of prostate carcinoma: clinical and statistical survey of 1,818 cases. JAMA. 1950;143:1317
  5. Oh W. The evolving role of estrogen therapy in prostate cancer. Clin Prostate Cancer. 2002;1:81
  6. Byar DP, Corle DK. Hormone therapy for prostate cancer: results of the Veterans Administration Cooperative Urological Research Group studies. NCI Monogr. 1988;7:165
  7. Cancer Topics. National Cancer Institute. http://www.cancer.gov/cancertopics/pdq/treatment/prostate/HealthProfessional/page8. Accessed December 20, 2006.
  8. Premarin label. Food and Drug Administration. http://www.fda.gov/cder/foi/label/2003/04782s129lbl.pdf. Accessed December 20, 2006.
  9. Droz JP, De Smedt E, Kattan J, Keuppens F, Khoury S, Mahler C, et al. Phase I trial of high-dose fosfestrol in hormone refractory adenocarcinoma of the prostate. Prostate. 1994;24:62
  10. Takezawa Y, Nakata S, Kobayashi M, Kosaku N, Fukabori Y, Yamanaka H. Moderate dose diethylstilbestrol diphosphate therapy in hormone refractory prostate cancer. Scand J Urol Nephrol. 2001;35:283
  11. Smith DC, Redman BG, Flaherty LE, Li L, Strawderman M, Pienta KJ. A phase II trial of oral diethylstilbestrol as a second-line hormonal agent in advanced prostate cancer. Urology. 1998;52:257
  12. Shahidi M, Norman A, Gadd J, Simpson J, Huddart R, Horwich A, et al. Prospective review of diethylstilbestrol in advanced prostate cancer no longer responding to androgen suppression. Proc Am Soc Clin Oncol. 2001;20:176b;abstract 2455
  13. Oh W, Kantoff P, Weinberg V, Jones G, Rini B, Derynck M, et al. Prospective, multicenter, randomized phase II trial of the herbal supplement, PC-SPES, and diethylstilbestrol in patients with androgen independent prostate cancer. J Clin Oncol. 2004;22:3705
  14. Ho S. Estrogens and anti-estrogens: key mediators of prostate carcinogenesis and new therapeutic candidates. J Cell Biochem. 2004;91:491
  15. Zhu Y, Cai L, Huang Y, Fish J, Wang L, Zhang Z, et al. Receptor isoform and ligand-specific modulation of dihydrotestosterone-induced prosate specific antigen gene expression and prostate tumor growth by estrogens. J Androl. 2005;26:500
  16. Kitahara S, Umeda H, Yano M, Koga F, Sumi S, Moriguchi H, et al. Effects of intravenous administration of high dose diethylstilbestrol diphosphate on serum hormonal levels in patients with hormone refractory prostate cancer. Endocr J. 1999;46:659
  17. Small E, Halabi S, Dawson N, Stadler W, Rini B, Picus J, et al. Androgen withdrawal alone or in combination with ketoconazole in androgen-independent prostate cancer patients: a phase III trial. J Clin Oncol. 2004;22:1025
  18. Arnold J, Blackman M. Does DHEA exert direct effects on androgen and estrogen receptors, and does it promote or prevent prostate cancer?. Endocrinol. 2005;146:4565

 Supported by the Dunkin Donuts Rising Stars Research Fund.

PII: S0022-5347(07)00257-1

doi: 10.1016/j.juro.2007.01.119

The Journal of Urology
Volume 177, Issue 6 , Pages 2146-2150 , June 2007

Article Tools

* Image Usage & Resolution